
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
Costs Drive Medicaid's Reality : States have yet to determine the right path How to fund exchange navigators Expanding into global markets






